DX 2930

Drug Profile

DX 2930

Alternative Names: Anti-plasma kallikrein mAb; Anti-plasma kallikrein monoclonal antibody; DX-2930; SHP 643

Latest Information Update: 05 Jan 2017

Price : $50

At a glance

  • Originator Dyax
  • Developer Shire
  • Class Monoclonal antibodies; Skin disorder therapies
  • Mechanism of Action Plasma-kallikrein-inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Hereditary angioedema
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    Hereditary angioedema
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Hereditary angioedema
  • Preclinical Diabetic macular oedema

Most Recent Events

  • 01 Nov 2016 Shire completes enrolment in the phase III HELP study in Hereditary angioedema in USA, Jordan, Germany, Puerto Rico, Canada, Italy and United Kingdom
  • 01 May 2016 Phase-III clinical trials in Hereditary angioedema (In adolescents, Prevention, In adults) in Canada, Italy, Germany, Jordan, United Kingdom (SC) (NCT02741596)
  • 15 Apr 2016 Dyax plans the phase III HELP Study Extension™ trial for Hereditary angioedema (Prevention, In adolescents, In adults) in Canada, Germany, Italy, Jordan, United Kingdom and USA (SC) (NCT02741596)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top